Highlights Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Market Closed - Nasdaq Other stock markets 01:30:00 22/05/2024 am IST			5-day change	1st Jan Change
1.49 ^USD	+4.93%		+2.76%	-44.81%

22/04	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
22/04	Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	22/04	CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	16/04	MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04	CI
Sector Update: Health Care Stocks Softer Late Afternoon	12/04	MT
Sector Update: Health Care	12/04	MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	11/04	MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	11/04	CI
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	30/03	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02	CI
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	17/01	CI
Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.	17/01	CI
Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis	20/12	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Enlivex Therapeutics Ltd. announces an Equity Buyback for $1.5 million worth of its shares.	18/23/18	CI
Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis	11/23/11	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/23/02	CI
Enlivex Therapeutics Ltd. authorizes a Buyback Plan.	30/23/30	CI
Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States	02/23/02	CI
Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra? In Patients With Sepsis	31/23/31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Highlights

Filters